AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 4032389
Drug: Lavage with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavage with 800 ml of saline alone
Trial: 27787363
Drug: Alfentanil 5
RxNorm normalized name: alfentanil 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 5 μg/kg immediately before propofol administration
Trial: 27787363
Drug: Alfentanil 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 2.5 μg/kg immediately before propofol administration
Trial: 27787363
Drug: Alfentanil 5
RxNorm normalized name: alfentanil 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 5 μg/kg 2 minutes before propofol administration
Trial: 27787363
Drug: Propofol administration
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administration alone (control group 5)
Trial: 24867835
Drug: Botox treatment
RxNorm normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox treatment
Trial: 18173402
Drug: Natural bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural bone mineral in combination with a collagen membrane (NBM+CM)
Trial: 3521842
Drug: Intraperitoneal (IP)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (IP) 5-Fluorouracil (5-FU) chemotherapy
Trial: 3521842
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) 5-Fluorouracil (5-FU) chemotherapy
Trial: 3521842
Drug: Pelvic radiation
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic radiation therapy
Trial: 3521842
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil (5-FU) chemotherapy (both IP and IV)
Trial: 20233669
Drug: ReNu MultiPlus
RxNorm normalized name: ReNu MultiPlus No-Rub Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReNu MultiPlus Multipurpose Solution with PureVision silicon hydrogel contact lens
Trial: 18519845
Drug: Lisinopril (angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (angiotensin-converting enzyme blocker)
Trial: 18519845
Drug: Both medications
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both medications (Lisinopril and Atenolol)
Trial: 12499819
Drug: Concurrent chemo‐radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemo‐radiation therapy (external beam radiotherapy 4,500 cGy over 5 weeks and intrahepatic arterial 5‐FU infusion 500 mg on days 1-5 and 30-35)
Trial: 12499819
Drug: Intrahepatic arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrahepatic arterial cisplatin infusion (80 mg/m(2))
Trial: 10417455
Drug: Antiplatelet drug
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet drug therapy
Trial: 7739736
Drug: Hib vaccine
RxNorm normalized name: ActHIB vaccine 0.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib vaccine (administered at 3, 4, 5, and 11 months)
Trial: 6996929
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g magnesium dithiosalicylate daily
Trial: 6996929
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g aspirin daily
Trial: 29089356
Drug: Spironolactone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (40 mg orally, twice daily) for 2 months
Trial: 25040433
Drug: Tablet-based interactive
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based interactive distraction (TBID)
Trial: 25040433
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg·kg(‐1); 20 mg max)
Trial: 11136260
Drug: Inhaled triamcinolone
RxNorm normalized name: triamcinolone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled triamcinolone acetonide 600 microg twice daily
Trial: 29735484
Drug: Inclisiran 300
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 300 mg 2-dose regimen (100 mg on day 1 and 300 mg on day 90)
Trial: 29735484
Drug: Inclisiran 300
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 300 mg 2-dose regimen
Trial: 23044303
Drug: Metformin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (n = 41)
Trial: 23044303
Drug: Antioxidant treatment
RxNorm normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant treatment using lipoic acid
Trial: 20492627
Drug: Shampoo treatment
RxNorm normalized name: Head & Shoulders Damage Treatment Shampoo Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shampoo treatment with ultrapure soft water (UPSW)
Trial: 20492627
Drug: Shampoo treatment
RxNorm normalized name: Head & Shoulders Damage Treatment Shampoo Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shampoo treatment with tap water
Trial: 11921320
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus hormonal therapy
Trial: 9696733
Drug: Primaquine, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine, 30 mg/d for 15 weeks
Trial: 1115011
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg of pyridoxine hydrochloride
Trial: 1115011
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg of pyridoxine hydrochloride
Trial: 1115011
Drug: 20.0 mg
RxNorm normalized name: RUXOLITINIB 20.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20.0 mg of pyridoxine hydrochloride
Trial: 20176498
Drug: High-dose GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GH group (0.012 mg/kg/day)
Trial: 20176498
Drug: Low-dose GH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GH group (0.006 mg/kg/day)
Trial: 18803944
Drug: Oral D-chiro-inositol
RxNorm normalized name: chiro-inositol, (+)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral D-chiro-inositol (DCI) supplementation
Trial: 12368782
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine infusion for 48 hours
Trial: 12368782
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion for 48 hours (placebo)
Trial: 10211628
Drug: Oral 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-aminolevulinic acid (ALA) administration to normal volunteers
Trial: 10211628
Drug: Oral 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-aminolevulinic acid (ALA) administration
Trial: 8585739
Drug: Amoxicillin-clavulanate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (10 days)
Trial: 6123836
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg every 8 h for three days postoperatively)
Trial: 31447077
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) + Abiraterone acetate and prednisolone (AAP)
Trial: 17606474
Drug: Dietary 5-HT
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary 5-HT stimulation (tryptophan-rich alpha-lactalbumin, 4.8 g/100 g TRP)
Trial: 17606474
Drug: Placebo protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo protein (1.4 g/100 g TRP)
Trial: 25728808
Drug: Vancomycin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (125 mg four times a day for 3 days, followed by 125-500 mg/day every 2-3 days for at least 3 weeks)
Trial: 23380105
Drug: Intravenous valproic
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous valproic acid (iVPA) 400 mg
Trial: 23380105
Drug: Intramuscular metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular metoclopramide + subcutaneous sumatriptan (10 mg + 6 mg)
Trial: 19391535
Drug: Medication (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (oral administration of Vit E and Vit C)
Trial: 16805717
Drug: Antidiabetic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic treatments (e.g., thiazolidinediones)
Trial: 6383741
Drug: Lorcainide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcainide (100 mg twice daily or three times daily)
Trial: 6383741
Drug: Quinidine gluconate
RxNorm normalized name: Quinidine Gluconate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine gluconate (324 mg three times daily)
Trial: 21704964
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab monthly for 12 months
Trial: 29575941
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab monthly for 4 months followed by pro re nata injections
Trial: 29575941
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg ranibizumab monthly for 12 months
Trial: 29575941
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg ranibizumab monthly for 4 months followed by pro re nata injections
Trial: 29575941
Drug: High-dose ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ranibizumab
Trial: 29575941
Drug: Conventional-dose ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional-dose ranibizumab
Trial: 19834507
Drug: Topical Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cyclosporine A (CsA) and artificial tear-drop treatment
Trial: 19834507
Drug: Topical artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical artificial tear-drop treatment
Trial: 12970812
Drug: Verbal or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal or written informed consent prior to administration of Rh immune globulin
Trial: 9658375
Drug: Combined hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hepatitis A/hepatitis B vaccine
Trial: 29331328
Drug: High-Flow Nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Nasal Cannula (HFNC) oxygen therapy
Trial: 28298878
Drug: Conventional Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Oxygen Therapy (COG)
Trial: 27765582
Drug: TXA Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA Dose I ‐ 1 g bolus followed by 1 g infusion over 8 h
Trial: 27765582
Drug: TXA Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA Dose II ‐ 1 g bolus followed by 10 mg/kg/hr until the end of surgery
Trial: 24311515
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g EPA-rich lipid for 12 weeks
Trial: 18589448
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (n = 76)
Trial: 10491451
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose fluticasone propionate (2000 microg/day, FP2000)
Trial: 10491451
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (30 mg/day)
Trial: 10491451
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose fluticasone propionate (500 microg/day, FP500)
Trial: 8367920
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate (3.6 mg s.c. once every four weeks) and flutamide (250 mg three times daily)
Trial: 31578169
Drug: Pirfenidone 2403
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone 2403 mg daily
Trial: 26810904
Drug: Continuous sciatic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sciatic block (continuous infusion)
Trial: 25363150
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments including rituximab
Trial: 28459603
Drug: Open-loop (OL)
RxNorm normalized name: limonen-10-ol, (+)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-loop (OL) conventional pump therapy (OL1/OL2)
Trial: 23786436
Drug: Trust in
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trust in racial equity of treatment
Trial: 18678610
Drug: Technosphere insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Technosphere insulin
Trial: 14557959
Drug: Azithromycin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1000 mg, single oral dose)
Trial: 14557959
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg, single oral dose)
Trial: 3710012
Drug: Saline (154
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (154 mmol/l)
Trial: 27916047
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg atorvastatin (standard group)
Trial: 27916047
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg atorvastatin (intensive group)
Trial: 22525762
Drug: DDEA 2.32%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDEA 2.32% gel bid
Trial: 22525762
Drug: DDEA 2.32%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDEA 2.32% gel tid
Trial: 22525762
Drug: DDEA 2.32%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDEA 2.32% gel bid or tid
Trial: 22525762
Drug: DDEA 2.32%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDEA 2.32% gel
Trial: 12009244
Drug: VIP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP regimen (vindesine 3 mg/m² on days 1 and 8, ifosfamide 1300 mg/m² on days 1-5, cisplatin 20 mg/m² on days 1-5)
Trial: 12009244
Drug: VP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VP regimen (vindesine and cisplatin with the same dose and schedule as VIP)
Trial: 10047931
Drug: Rimantadine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimantadine at doses of 100 to 300 mg/d
Trial: 31081862
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic blood pressure target of 110-139 mm Hg)
Trial: 31081862
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (systolic blood pressure target of 140-179 mm Hg)
Trial: 28088223
Drug: Early integrated
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early integrated treatment
Trial: 24079817
Drug: Aqueous intranasal
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous intranasal corticosteroid (INS) formulation
Trial: 24079817
Drug: Aerosol intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol intranasal corticosteroid (INS) formulation
Trial: 24079817
Drug: Allergic Rhinitis
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergic Rhinitis Treatment Satisfaction and Preference (ARTSP) scale
Trial: 24079817
Drug: Treatment satisfaction
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment satisfaction subscales
Trial: 21865946
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of p53 and v-Ki-ras2 mutations
Trial: 21865946
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of p53 and either v-Ki-ras2 mutation or cyclin D1 G870A (AA) polymorphism or methylenetetrahydrofolate reductase (NAD(P)H) C677T (TT) polymorphism
Trial: 19262477
Drug: Olmesartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan + Calcium Channel Blocker (ARB/CCB group)
Trial: 19262477
Drug: Olmesartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan + Diuretic (ARB/diuretic group)
Trial: 11737955
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (100 mg dl-alpha-tocopheryl acetate, 200 mg ascorbic acid, 2 mg beta-carotene)
Trial: 8112368
Drug: Didanosine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine as a single agent
Trial: 8112368
Drug: Didanosine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine with metoclopramide (10 mg IV)
Trial: 8112368
Drug: Didanosine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine with loperamide (4 doses of 4 mg each)
Trial: 27640067
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg SCH 527123
Trial: 22119219
Drug: 2-L PEG+ascorbic
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L PEG+ascorbic acid
Trial: 28939500
Drug: 4-L PEG
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-L PEG
Trial: 20102922
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg once per day
Trial: 20102922
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg once per day
Trial: 15823184
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of beclomethasone dipropionate 250 microg b.i.d and slow-release theophylline 0.2 g b.i.d (SRT/BDP group)
Trial: 10614676
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined 2 mg estradiol and 1 mg norethisterone acetate (E+NETA) daily
Trial: 8540760
Drug: Zidovudine 50
RxNorm normalized name: ZIDOVUDINE 50MG/5ML SYRUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine 50 mg, 100 mg, 200 mg combined with Didanosine 67 mg, 167 mg, 250 mg
Trial: 1784148
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (specific drugs not mentioned)
Trial: 7092500
Drug: Schedule for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule for Affective Disorders and Schizophrenia‐Lifetime (SADS‐L)
Trial: 7092500
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of SADS‐L and NIMH‐DIS
Trial: 27730198
Drug: Umeclidinium 62.5
RxNorm normalized name: UMECLIDINIUM 62.5MCG 7D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium 62.5 µg
Trial: 27730198
Drug: Glycopyrronium 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium 50 µg
Trial: 24284985
Drug: 5% cis-urocanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% cis-urocanic acid emulsion cream
Trial: 19156355
Drug: Atomoxetine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (up to 1.2 mg/kg/day or 80 mg/day) with psychoeducation
Trial: 18087899
Drug: Low Intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Intensity Laser Therapy (LILT)
Trial: 12616983
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive preparations (30 micrograms ethinylestradiol with either 75 micrograms gestodene or 150 micrograms desogestrel)
Trial: 12616983
Drug: 17 beta-oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta-oestradiol (2 mg)
Trial: 12616983
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive preparations (30 micrograms ethinylestradiol)
Trial: 336002
Drug: L-5-hydroxytryptophan (L-5-HTP)
RxNorm normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-hydroxytryptophan (L-5-HTP)
Trial: 8819814
Drug: Flecainide 150‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide 150‐300 mg/die